BURLINGTON, Mass.--(BUSINESS WIRE)--Infraredx, Inc., an intravascular imaging company committed to advancing the diagnosis and management of coronary artery disease, today announced the enrollment of 1,000 patients in the Lipid-Rich Plaque (LRP) Study. The LRP Study is a prospective, multi-center clinical trial designed to identify a correlation between lipid-rich plaques detected by Infraredx’s TVC Imaging SystemTM and the occurrence of a cardiac event within two years. The first-in-class dual
| < Prev | Next > |
|---|
